Maroun Richard E 4
4 · APP Pharmaceuticals, Inc. · Filed Sep 15, 2008
Insider Transaction Report
Form 4
Maroun Richard E
Chief Administrative Officer
Transactions
- Disposition to Issuer
Incentive Stock Option
2008-09-10$15.34/sh−26,064$399,822→ 0 totalExercise: $7.66Exp: 2016-05-19→ Common Stock (26,064 underlying) - Disposition to Issuer
Common Stock
2008-09-10−41→ 0 total(indirect: Stock owned by Son) - Disposition to Issuer
Common Stock
2008-09-10−73→ 0 total(indirect: Stock owned by Daughter) - Disposition to Issuer
Common Stock
2008-09-10−100→ 0 total - Disposition to Issuer
Nonqualified Stock Option (Right to Purchase)
2008-09-10$15.34/sh−42,300$648,882→ 0 totalExercise: $7.66Exp: 2016-05-19→ Common Stock (42,300 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of July 6, 2008, among Fresenius SE, Fresenenius Kabi Pharmaceuticals Holding, Inc. (formerly Frensenius Kabi Pharmaceuticals Holding LLC), Fresenius Kabi Pharmaceuticals, LLC (?Merger Sub?) and APP Pharmaceuticals, Inc. (?APP?), whereby Merger Sub merged into APP with APP continuing as the surviving company and an indirect wholly owned subsidiary of Fresenius SE (the ?Merger?), in exchange for (x) an amount in cash equal to $23.00 plus (y) a contingent value right issued by Holdco.
- [F2]Pursuant to the Merger, this option, which was granted on May 19, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $199,650, which represents the excess of $23.00 per share over the exercise price per share of this option.
- [F3]Pursuant to the Merger, this option, which was granted on May 19, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $324,018, which represents the excess of $23.00 per share over the exercise price per share of this option.